查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961092

獸醫再生醫學市場－全球產業規模、佔有率、趨勢、機會和預測：按動物類型、產品、應用、最終用途、地區和競爭格局分類，2021-2031年

Veterinary Regenerative Medicine Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Animal Type, By Product, By Application, By End-Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球獸醫再生醫學市場預計將大幅成長，從 2025 年的 3.2172 億美元成長到 2031 年的 5.9366 億美元，複合年成長率為 10.75%。

該市場專注於利用幹細胞療法、富血小板血漿（PRP）和組織工程等生物療法來修復或替換受損的動物組織。推動這一市場擴張的關鍵因素包括骨關節炎等慢性整形外科疾病的日益普遍以及寵物人性化的趨勢。這促使飼主尋求更先進的醫療干預措施，而對動物醫療保健的大量投資也支持了這項需求。根據美國寵物用品協會（APPA）預測，到2024年，美國寵物產業的總支出預計將達到1,506億美元，這意味著獸醫服務和醫療保健領域的資本投入將大幅成長。

市場概覽
預測期 2027-2031
市場規模：2025年 3.2172億美元
市場規模：2031年 5.9366億美元
複合年成長率：2026-2031年 10.75%
成長最快的細分市場 大型動物
最大的市場 北美洲

阻礙市場成長的主要障礙之一是研發和實施這些特殊治療方法的高成本。生物材料的採集和加工成本往往導致價格高昂，限制了許多寵物飼主的取得途徑。此外，缺乏全球統一的法規結構也為製造商帶來了合規方面的複雜性。這些監管方面的挑戰可能會延緩主要國際地區新型再生醫學產品的核准和商業化進程，進一步阻礙市場擴張。

市場促進因素

寵物人性化的趨勢日益增強，寵物飼養率不斷攀升，這成為全球獸醫再生醫學市場發展的重要驅動力。隨著飼主越來越將伴侶動物視為家庭成員，他們也越來越願意投資能夠延長壽命、緩解慢性疼痛的治療方法。這種情感紐帶推動了對幹細胞和富血小板血漿療法的需求，尤其針對患有老齡化退化性整形外科疾病的老年犬。美國獸醫協會的報告顯示，到2025年10月，美國犬隻數量將增加至8,730萬隻，這充分體現了這個市場的巨大潛力。各公司正積極籌集資金，以可擴展的解決方案滿足這項需求。例如，Gallant Therapeutics公司於2025年6月完成了1,800萬美元的B輪資金籌措，用於其即用型幹細胞產品的商業化。

此外，寵物醫療保健成本的不斷上漲和寵物保險的日益普及，正在彌合臨床可及性和經濟負擔之間的差距，從而加速市場成長。雖然高昂的費用歷來阻礙再生醫學的廣泛應用，但寵物保險的普及正在消除這些經濟障礙。隨著保險範圍擴大到復健和再生醫學手術，獸醫現在能夠在治療早期就開立這些有效的治療方法。這種向財務保障的轉變勢頭強勁，北美寵物健康保險協會 (NAPHIA) 報告稱，到 2025 年 4 月，北美投保寵物的總數將達到 703 萬隻，同比成長 12.2%。

市場挑戰

再生醫學研發和應用的高昂成本是其廣泛應用的主要障礙。儘管人們對改善動物醫療保健的需求日益成長，但幹細胞療法和組織工程的高昂費用使許多寵物飼主難以負擔。由於大多數獸醫費用需要自付而非透過全面的保險計劃支付，這些特殊治療的經濟負擔往往迫使寵物主人選擇傳統的、費用較低的治療方法，例如治療骨關節炎等疾病。這種價格敏感度將客戶群限制在富裕的小眾群中，阻礙了市場成熟所需的規模化發展。

這些經濟限制因素因近期該產業消費者支出的變化而進一步凸顯，這與整個產業資本成長的整體趨勢背道而馳。根據美國獸醫協會（AVMA）預測，2024年獸醫總支出將年減4%。儘管消費者對高階醫療服務的需求依然旺盛，但該行業的這一萎縮表明實際購買力正在下降。因此，製造商難以實現規模經濟以降低高昂的治療成本，從而形成惡性循環，阻礙了其在關鍵地區的市場滲透。

市場趨勢

該行業正積極從以患者為中心的內部製備模式轉向生產可擴展的、具有標準化藥物功能的同種異體「現成」療法。這項轉變將使企業能夠克服與單例治療相關的物流和財務瓶頸，並生產出穩定、受監管的批次產品以供大規模分銷。為了響應這一向工業化規模再生醫學生產的趨勢，生物技術公司正撥出大量資金用於建造專門的生產基礎設施，以滿足未來的商業需求。例如，根據《波蘭洞察》（Polish Insight）2025年9月報道，BioCeltics計劃透過股票上市籌集資金，用於建造一座新的大型幹細胞生產設施，該營運成本5000萬波幣。

市場擴張的進一步驅動力在於研究方向的多元化，從犬類整形外科的常規研究轉向其他伴侶動物（尤其是貓科動物）複雜慢性疾病的專科治療。這一趨勢旨在解決貓科動物治療選擇不足這一長期難題，將研發資源集中在腎衰竭和心肌病等高發病（這些疾病需要個體化的生物干預，而非跨物種的適應性治療）。這種物種特異性方法的推進勢頭在學術界和產業界研究提案的激增中可見一斑。 2024年12月，莫里斯動物基金會報告稱，已收到50多份專門用於推進貓科動物健康科學的津貼提案，其中包括慢性腎臟病和心臟病的研究。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球獸醫再生醫學市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 動物種類（小型動物、大型動物）
    • 依產品（幹細胞、其他）
    • 按應用領域（整形外科、創傷/創傷護理、其他）
    • 依用途（動物醫院/診所、動物研究機構）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美獸醫再生醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲獸醫再生醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區獸醫再生醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲獸醫再生醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲獸醫再生醫學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球獸醫再生醫學市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Boehringer Ingelheim International GmbH
  • Zoetis Inc.
  • Dechra Pharmaceuticals PLC
  • Integra LifeSciences Incorporation
  • Vetherapy
  • VetStem, Inc.
  • Ardent Animal Health, LLC
  • Enso Discoveries, LLC
  • Animal Cell Therapies, Inc.
  • Vetbiologics LLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23984

The Global Veterinary Regenerative Medicine Market is projected to experience substantial growth, expanding from USD 321.72 Million in 2025 to USD 593.66 Million by 2031 at a CAGR of 10.75%. This market focuses on utilizing biological therapies, such as stem cell treatments, platelet-rich plasma, and tissue engineering, to repair or replace damaged animal tissues. Key drivers fueling this expansion include the rising prevalence of chronic orthopedic conditions like osteoarthritis and the growing trend of pet humanization, which motivates owners to seek advanced medical interventions. This demand is underpinned by significant financial dedication to animal healthcare; the American Pet Products Association projected that total U.S. pet industry expenditures would reach 150.6 billion dollars in 2024, signaling a major increase in capital allocation toward veterinary services and wellness.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 321.72 Million
Market Size 2031USD 593.66 Million
CAGR 2026-203110.75%
Fastest Growing SegmentLarge Animals
Largest MarketNorth America

One significant obstacle hindering market growth is the high cost associated with developing and administering these specialized therapies. The expenses involved in harvesting and processing biological materials often result in prohibitive prices that limit accessibility for a large portion of pet owners. Furthermore, the absence of globally harmonized regulatory frameworks introduces compliance complexities for manufacturers. These regulatory challenges can delay the approval and commercialization of new regenerative products in key international regions, further impeding market expansion.

Market Driver

The increasing trend of pet humanization and rising adoption rates act as fundamental catalysts for the Global Veterinary Regenerative Medicine Market. As owners increasingly view their companion animals as integral family members, they are more willing to invest in advanced treatments that extend lifespan and alleviate chronic pain. This emotional bond drives the demand for stem cell and platelet-rich plasma therapies, particularly for aging dogs suffering from degenerative orthopedic conditions. The magnitude of this opportunity is underscored by the American Veterinary Medical Association, which noted that the U.S. dog population grew to 87.3 million in October 2025. To meet this demand with scalable solutions, companies are securing significant capital, as demonstrated when Gallant Therapeutics closed an 18 million dollar Series B financing round in June 2025 to commercialize off-the-shelf stem cell products.

Additionally, growing pet healthcare expenditure and the increasing penetration of pet insurance are accelerating market expansion by bridging the gap between clinical availability and affordability. While high costs have historically restricted the reach of regenerative therapies, the widespread adoption of pet insurance is dismantling these financial barriers. As insurance coverage expands to include rehabilitative and regenerative procedures, veterinarians are empowered to prescribe these effective treatments earlier in the care process. This shift toward financial protection is robust; the North American Pet Health Insurance Association reported that the total number of insured pets in North America reached 7.03 million in April 2025, representing a 12.2 percent increase from the previous year.

Market Challenge

The high costs associated with developing and administering regenerative therapies present a significant barrier to their widespread adoption. Although the demand for improved animal healthcare is rising, the substantial expense required for stem cell treatments and tissue engineering places these options out of reach for a vast demographic of pet owners. Since the majority of veterinary costs are paid directly out-of-pocket rather than through comprehensive insurance plans, the economic burden of such specialized care often forces clients to choose conventional, less expensive management strategies for conditions like osteoarthritis. This price sensitivity limits the customer base to a niche segment of affluent clients, thereby stalling the volume growth necessary for the market to mature.

This financial constraint is further highlighted by recent shifts in consumer expenditure within the sector, which contradict the broader trend of increased industry capitalization. According to the American Veterinary Medical Association, overall veterinary spending decreased by 4% in 2024 compared to the previous year. This contraction in specific veterinary allocation indicates that despite the emotional drive for premium care, actual purchasing power is tightening. Consequently, manufacturers face difficulties in achieving the economies of scale needed to reduce prohibitive treatment prices, creating a cycle that restricts market penetration in key regions.

Market Trends

The industry is aggressively pivoting from autologous, patient-side processing toward the manufacturing of scalable, allogeneic "off-the-shelf" therapies that operate like standard pharmaceuticals. This transition allows companies to overcome the logistical and financial bottlenecks of single-patient treatments by producing consistent, regulatorily compliant batches for mass distribution. Reflecting this move toward industrial-scale regenerative manufacturing, biotechnology firms are securing significant capital to build specialized production infrastructure to meet future commercial demand. For instance, Poland Insight reported in September 2025 that Bioceltix is planning a share issue to finance the construction of a new large-scale stem cell production facility with a total project value of 50 million Polish Zloty.

Market expansion is further driven by a diversification of research beyond general canine orthopedics into specialized treatments for complex chronic conditions in other companion species, particularly felines. This trend addresses the historical lack of therapeutic options for cats by directing R&D resources toward high-prevalence ailments such as renal failure and cardiomyopathy, which require tailored biological interventions rather than cross-species adaptations. The momentum behind this species-targeted approach is evident in the surging volume of academic and industrial research proposals; the Morris Animal Foundation reported in December 2024 that it received more than 50 grant proposals specifically dedicated to advancing feline health science, including studies on chronic kidney disease and heart disease.

Key Market Players

  • Boehringer Ingelheim International GmbH
  • Zoetis Inc.
  • Dechra Pharmaceuticals PLC
  • Integra LifeSciences Incorporation
  • Vetherapy
  • VetStem, Inc.
  • Ardent Animal Health, LLC
  • Enso Discoveries, LLC
  • Animal Cell Therapies, Inc.
  • Vetbiologics LLC

Report Scope

In this report, the Global Veterinary Regenerative Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Regenerative Medicine Market, By Animal Type

  • Small Animals
  • Large Animals

Veterinary Regenerative Medicine Market, By Product

  • Stem Cells
  • Others

Veterinary Regenerative Medicine Market, By Application

  • Orthopedics
  • Trauma/Wound Care
  • Others

Veterinary Regenerative Medicine Market, By End-Use

  • Veterinary Hospitals/Clinics
  • Veterinary Research Institutes

Veterinary Regenerative Medicine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Regenerative Medicine Market.

Available Customizations:

Global Veterinary Regenerative Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Regenerative Medicine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Small Animals, Large Animals)
    • 5.2.2. By Product (Stem Cells, Others)
    • 5.2.3. By Application (Orthopedics, Trauma/Wound Care, Others)
    • 5.2.4. By End-Use (Veterinary Hospitals/Clinics, Veterinary Research Institutes)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Veterinary Regenerative Medicine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End-Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Veterinary Regenerative Medicine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-Use
    • 6.3.2. Canada Veterinary Regenerative Medicine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-Use
    • 6.3.3. Mexico Veterinary Regenerative Medicine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-Use

7. Europe Veterinary Regenerative Medicine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End-Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Veterinary Regenerative Medicine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-Use
    • 7.3.2. France Veterinary Regenerative Medicine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-Use
    • 7.3.3. United Kingdom Veterinary Regenerative Medicine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-Use
    • 7.3.4. Italy Veterinary Regenerative Medicine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-Use
    • 7.3.5. Spain Veterinary Regenerative Medicine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-Use

8. Asia Pacific Veterinary Regenerative Medicine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End-Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Veterinary Regenerative Medicine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-Use
    • 8.3.2. India Veterinary Regenerative Medicine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-Use
    • 8.3.3. Japan Veterinary Regenerative Medicine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-Use
    • 8.3.4. South Korea Veterinary Regenerative Medicine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End-Use
    • 8.3.5. Australia Veterinary Regenerative Medicine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End-Use

9. Middle East & Africa Veterinary Regenerative Medicine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End-Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Veterinary Regenerative Medicine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-Use
    • 9.3.2. UAE Veterinary Regenerative Medicine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-Use
    • 9.3.3. South Africa Veterinary Regenerative Medicine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-Use

10. South America Veterinary Regenerative Medicine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End-Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Veterinary Regenerative Medicine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-Use
    • 10.3.2. Colombia Veterinary Regenerative Medicine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-Use
    • 10.3.3. Argentina Veterinary Regenerative Medicine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Veterinary Regenerative Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Boehringer Ingelheim International GmbH
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Zoetis Inc.
  • 15.3. Dechra Pharmaceuticals PLC
  • 15.4. Integra LifeSciences Incorporation
  • 15.5. Vetherapy
  • 15.6. VetStem, Inc.
  • 15.7. Ardent Animal Health, LLC
  • 15.8. Enso Discoveries, LLC
  • 15.9. Animal Cell Therapies, Inc.
  • 15.10. Vetbiologics LLC

16. Strategic Recommendations

17. About Us & Disclaimer